CIT, a safety and health research laboratory and Stemina Biomarker have made a strategic partnership. CIT is independent, science driven, non clinical CRO (contract research organization). It has its specialization in safety and health research. It carries out numerous projects for companies working abroad. These international companies are working in the field of human and veterinary pharmaceuticals, biotechnology, agrochemicals, chemicals and consumer products. As a result of this partnership CIT will be distributing Stemina’s DevTOX assay in the European market. It will be working for the validation of stem cell international based tests under REACH.
This REACH initiative involves manufacturers and importers to register and then test the chemicals and their composition. DevTOX makes use of human embryonic cells as compared to isolate menstrual blood stem cells. These human embryonic stem cells test chemicals, pharmaceuticals and formulations. These have a negative impact especially on human body and create a toxic effect. This is the reason which causes several birth defects if a woman is exposed to heavy use of chemicals during pregnancy. DevTOX is fully capable to model toxicity during embryo development with ninety percent accuracy level in case of chemicals whose role during human embryo development is known.
Stemina has developed DevTOX by exposing human embryonic cells to a set of drugs like thalidomide. It is used because of the fact that the effect of this drug on the human embryo is known. The effect on the metabolism of the abundant stem cells is analyzed after this. Analysis is done by using proprietary metabolomics platform technology. Human embryonic cells were extracted in the year of 1998 by Dr James Thomson at the Wisconsin University. After its success, the research was later on approved to be used in other developed countries. This research helped to understand embryo development in humans and agents responsible for birth defects on the embryo.
However, the concept of menstrual blood banking is recent and it is being speculated that this discovery will further reveal many new secrets in medical history. Stemina studies responses from hES and other cells derived from them such as heart cells and neurons for drug testing. The company CEO says that they are really very excited with their partnership with CIT in Europe. It is a wonderful achievement for both the companies. The amazing combination of hES cell technology and forty years of experience in toxicology and testing are going to thunder the world. The company’s clients will be able to access most innovative methods of toxicity evaluation and safety of chemicals.
No comments:
Post a Comment